Intellipharmaceutics International (IPCIF) 20-F2016 FY Annual report (foreign)

Filed: 28 Feb 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Addiction, addressed, addressing, Affordable, American, AstraZeneca, Aug, bioinequivalence, bioinequivalent, border, burning, Century, Chinese, cited, compression, concept, crossover, customary, Dawson, defeat, Depositary, deterring, differentiate, differentiated, disagreement, euphoria, feeling, fewer, flag, flame, fumarate, gap, Glucophage, Hatch, heat, hereto, hinder, House, impracticable, inadequate, incremental, inhale, intentionally, irrespective, KeppraXR, kind, Lamictal, Lamotrigine, letter, Libin, literature, Logiq, main, Mallinckrodt, metformin, MNP, Molecular, noncash, OdidiOntario, Orange, orphan, overstated, partly, pattern, PDUFA, pediatric, perspective, presidential, proof, purview, put, quetiapine, ratio, repeal, Richmond, Senate, Seroquel, stayed, step, stiffer, trend, Trump, unclear, understated, understatement, underwriter, Underwriting, unmodified, unresolved, warning, Waxman, West

Removed: Accession, AG, bankruptcy, Celgene, contrast, deem, defense, Delaware, dismissal, District, Elan, Expenditure, gave, generating, harmonization, indemnity, injection, intranasal, Ireland, Jersey, Ministry, plc, Polysaccharide, reclassification, reformulated, refusing, title, XBRL, Yonge

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IPCIF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 15.2

	Deloitte LLP Bay Adelaide East 22 Adelaide Street West Suite 200 Toronto ON M5H 0A9 Canada Tel: 416-601-6150 Fax: 416-601-6610 www.deloitte.ca

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in Registration Statement No(s). 333-172796 and 333-196112 on Form F-3 of our report dated February 26, 2016, relating to the 2015 consolidated financial statements of Intellipharmaceutics International Inc. and subsidiaries (the “Company”) for the years ended November 30, 2015 and 2014 (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the conditions and events that raise substantial doubt on the Company’s ability to continue as a going concern) appearing in this Annual Report on Form 20-F for the year ended November 30, 2016.

/s/ Deloitte LLP

Chartered Professional Accountants

Licensed Public Accountants

February 27, 2017

Toronto, Canada